What Is CJC-1295 No DAC?
CJC-1295 no DAC is a synthetic analog based on the 1–29 amino acid region of growth hormone-releasing hormone (GHRH). It belongs to the modified GHRH peptide class and is studied in the context of structure–activity relationships, including how sequence modifications affect interaction with the GHRH receptor.
The primary molecular target is the GHRH receptor, which is expressed on anterior pituitary somatotroph cells. Published research on GHRH(1–29) analogs has examined receptor binding, peptide structure, and pituitary signaling. For CJC-1295 no DAC specifically, the available evidence is predominantly preclinical.
Research Overview Table
Chemical and Molecular Characteristics
CJC-1295 no DAC is a peptide molecule based on the GRF(1-29) framework. The reported molecular formula is C₁₅₂H₂₅₂N₄₄O₄₂, with a molecular weight of 3,367.9 g/mol. Peptide chemistry research has examined the GRF(1-29) framework extensively, including studies of sequence changes and C-terminal amidation.
Structural studies of GRF(1-29) peptides have also examined their conformational behavior. Circular dichroism and nuclear magnetic resonance research found that these peptides can adopt helical structures under particular solvent conditions, while their conformation can vary with the surrounding environment. These findings are relevant to understanding the physicochemical characteristics of modified GRF peptide structures.
Certificates:
Mechanism of Action Under Investigation
CJC-1295 No DAC is investigated for its interaction with the growth hormone-releasing hormone receptor (GHRH-R) on pituitary somatotroph cells. Following receptor activation, the associated Gs protein stimulates adenylyl cyclase, increasing intracellular cyclic AMP (cAMP). This cAMP-dependent signaling activates protein kinase A , which then regulates downstream cellular signaling through protein phosphorylation. Experimental studies of GRF signaling have directly measured GHRH-stimulated adenylyl cyclase activity and intracellular cAMP in purified somatotrophs.
The mechanism under investigation is therefore the receptor-mediated Gs/adenylyl cyclase/cAMP/PKA signaling cascade. Experimental studies have also examined downstream PKA-dependent effects on ion-channel activity in pituitary cells, providing evidence that the pathway extends beyond cAMP production alone.
Scientific Research Context
CJC-1295 No DAC appears in the scientific literature as a modified GHRH peptide for studying GHRH-related peptide structure and endocrine signaling. Research on related GRF(1–29) analogs includes peptide chemistry, receptor studies, pituitary-cell experiments, and animal models. The published evidence for this compound is primarily in vitro and preclinical, while much of the specific CJC-1295 literature concerns the DAC-containing form and should be distinguished from the no-DAC variant.
CJC-1295 No DAC Biology and Biological Pathways
Primary Biological Function
The growth hormone-releasing hormone receptor (GHRH-R) is found predominantly on pituitary somatotroph cells, where it is involved in regulating somatotroph activity. Research has also identified GHRH-R expression in tissues including the hypothalamus, kidney, and placenta.
Relevant Metabolic or Signaling Pathways
GHRH-R biology is closely associated with the cAMP signaling system. Published research has examined GHRH-R regulation of adenylyl cyclase, intracellular cAMP, protein kinase A, CREB, and Pit-1. MAP kinase signaling has also been investigated within the GHRH receptor system.
Tissue-Specific Biology
GHRH-R expression is most strongly associated with somatotrophs in the anterior pituitary, where immunohistochemical studies have localized the receptor to these cells in both rat and human tissue. Other studies have reported GHRH-R expression in the hypothalamus, kidney, placenta, and reproductive tissues, including the ovary, testis, and prostate. This distribution provides a basis for investigating differences in GHRH-R biology across pituitary and extra-pituitary tissues.
Experimental Biomarkers
Studies of the GHRH receptor system commonly measure receptor binding, adenylyl cyclase activity, and intracellular cAMP. Researchers have also examined CREB and Pit-1 as downstream markers in pituitary cells. These measures help track changes in GHRH receptor signaling and related cellular activity.
Laboratory Investigation Methods
Research on GRF(1–29) analogs has used receptor-binding assays, pituitary membrane preparations, adenylyl cyclase assays, cAMP measurements, and structure–activity studies. These methods are used to study how modified GRF peptides interact with receptors and how structural changes affect their activity.
Experimental Models Used in Published Research
Published research relevant to CJC-1295 No DAC comes mainly from studies of GRF(1–29) analogs. Experimental work has used primary anterior pituitary cells, pituitary membrane preparations, and rat models to study these peptides at different levels of biological complexity. Direct experimental research on CJC-1295 No DAC itself remains limited.
Pituitary Cell Models
Primary rat anterior pituitary cells have been used to study GRF(1–29) analogs in vitro. Researchers measure growth hormone release and intracellular cAMP in these cultures. This model provides a direct way to study pituitary responses, but cultured cells do not fully reflect the hormonal control of an intact organism.
Pituitary Membrane Preparations
Pituitary membrane preparations have been used to study how GRF analogs interact with pituitary receptors and affect adenylyl cyclase activity. This approach isolates receptor-related activity from the rest of the cell, making it useful for biochemical studies. Its main limitation is that isolated membranes do not reflect the full cellular environment.
Rodent Models
Rodent models have been used to study GRF(1–29) analogs in an intact biological setting. Researchers measure responses such as circulating growth hormone and pituitary responses after peptide exposure. These models add whole-animal context that cell studies cannot provide. But differences between rodent and human physiology limit how directly the findings can be applied to humans.
CJC-1295 No DAC Published Research
GRF(1–29) Structure–Activity Research
Published research has examined how changes to the GRF(1–29) sequence affect receptor interaction and peptide activity. Researchers have tested modified GRF peptides with different amino-acid substitutions and peptide-bond changes using biochemical assays and primary rat anterior pituitary cell cultures. This work provides the main experimental background for modified GRF peptides, but the tested compounds were not specifically identified as CJC-1295 No DAC.
GHRH Receptor Research
Published research has investigated how structural changes in GRF(1–29)-NH₂ analogs affect their interaction with GRF receptors and adenylate cyclase. One study compared 30 synthetic analogs using membrane preparations from rat anterior pituitary, liver, and pancreas. The work focused on receptor recognition and receptor-linked adenylate cyclase activity across the different tissue systems.
Peptide Structure and Conformation
Another area of research has focused on the physical structure of GRF analogs. Studies have examined amphiphilic properties, helical structure, and conformational changes produced by sequence modifications. Circular dichroism and molecular modeling have been used alongside biological testing in animal studies. This work provides structural information for the GRF(1–29) peptide class, but it does not establish compound-specific findings for CJC-1295 No DAC.
Pituitary and Animal Research
Published GRF(1–29) research has investigated modified peptides in cultured rat anterior pituitary cells and animal models. These studies have examined how structural changes in GRF analogs relate to their activity in pituitary and whole-animal systems. The available literature provides research context for modified GRF peptides, but direct experimental studies of CJC-1295 No DAC remain limited.
Direct Evidence for CJC-1295 No DAC
The available literature does not provide a large body of experimental studies specifically identifying CJC-1295 No DAC as the test compound. The principal CJC-1295 study in PubMed concerns the DAC-containing form. Therefore, findings from that study should not be presented as direct evidence for the No-DAC peptide.
Limitations of Current Research
Evidence Is Predominantly Preclinical
The available evidence for CJC-1295 No DAC is limited. Much of the relevant literature involves modified GRF(1–29) analogs rather than the specific compound. These studies have mainly used biochemical assays, pituitary cell systems, and animal models. As a result, the evidence base for CJC-1295 No DAC itself remains limited.
Human Clinical Evidence
Direct human clinical evidence for CJC-1295 No DAC is not established in the published literature. The human CJC-1295 studies identified in the literature investigated the DAC-containing form, including pharmacokinetic and clinical studies in healthy adults. Those findings cannot be used as direct clinical evidence for the No-DAC peptide.
Species Differences
Related GRF research has identified differences in peptide activity between species. Studies have compared GRF analogs in rat and human systems and found that some structural modifications can produce different receptor-related responses across species. These findings are relevant when interpreting animal data, but they do not provide direct evidence for CJC-1295 No DAC.
Study Design Limitations
Published GRF(1–29) studies have used different analogs, peptide modifications, tissue preparations, and assay systems. Some studies used pituitary membranes, while others used cultured pituitary cells or animal models. Because the compounds and experimental conditions vary between studies. the findings are not directly interchangeable or sufficient to define the properties of CJC-1295 No DAC specifically.
Independent Replication
The main limitation is the small amount of research directly focused on CJC-1295 No DAC. A much larger body of work concerns related GRF(1–29) analogs, while the specific No-DAC compound has not been independently evaluated across a broad range of studies.
Long-Term Evidence
Long-term evidence specific to CJC-1295 No DAC remains limited. Researchers have studied related GRF analogs over longer periods in animal models, but these involved different peptide structures. The longer-duration human studies of CJC-1295 used the DAC-containing form, so they do not provide direct long-term evidence for the No-DAC peptide.
Analytical Documentation
Reliable laboratory research depends on confirming the identity and purity of the peptide being studied. For CJC-1295 No DAC, HPLC can be used to assess peptide purity, while LC-MS can confirm molecular mass and support chemical identification. Related GRF(1–29) research has used HPLC and mass spectrometry to characterize modified GRF peptides.
Where detailed structural information is needed, NMR spectroscopy has also been used to examine the structure and conformation of GRF(1–29) derivatives. A Certificate of Analysis (CoA) can record batch-specific identity, purity, analytical methods, and test results. This documentation helps verify the material used in laboratory research. Analytical documentation confirms chemical identity and quality, not biological performance.
Storage and Laboratory Handling
CJC-1295 No DAC should be handled by qualified laboratory personnel using clean procedures that limit contamination and unnecessary exposure to environmental conditions. Published work on related GRF(1–29) peptides shows that these peptides can undergo chemical degradation and changes in stability under different conditions.
The material should be stored according to the product-specific storage specifications and kept in a properly closed, clearly labeled container when not in use. Because specific storage conditions for CJC-1295 No DAC are not well established in the published literature, they should not be inferred from studies of the DAC-containing form. The material is intended for qualified laboratory research use only.
Frequently asked questions
Why choose us?
Direct SARMs is an established supplier of research peptides. We are committed to product quality, reliable service, and helpful customer support.
Our European-made products undergo rigorous purity testing, with clear product information provided for each research material. We also aim to provide dependable shipping and a smooth ordering experience.
Our support team is available to assist with orders, shipping, payments, and general questions. At Direct SARMs, we aim to make the research supply process simple, clear, and reliable.